Advisors Asset Management, Inc. Amicus Therapeutics, Inc. Transaction History

Advisors Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 08, 2022	SELL	$9.82 - $12.75 $15,240 - $19,788	-1,552 Reduced 2.45%	61,738 $645,000
Q2 2022 Aug 08, 2022	SELL	$6.23 - $11.12 $82,198 - $146,717	-13,194 Reduced 17.25%	63,290 $680,000
Q1 2022 May 17, 2022	SELL	$7.89 - $12.48 $39,426 - $62,362	-4,997 Reduced 6.13%	76,484 $724,000
Q4 2021 Feb 15, 2022	SELL	$9.82 - $12.44 $13,207 - $16,731	-1,345 Reduced 1.62%	81,481 $941,000
Q3 2021 Nov 12, 2021	SELL	$8.74 - $11.84 $4,370 - $5,920	-500 Reduced 0.6%	82,826 $791,000
Q2 2021 Jul 30, 2021	BUY	$8.71 - $10.72 $39,839 - $49,033	4,574 Added 5.81%	83,326 $803,000
Q1 2021 May 07, 2021	BUY	$9.2 - $23.86 $305,265 - $791,698	33,181 Added 72.81%	78,752 $778,000
Q4 2020 Feb 12, 2021	BUY	$13.47 - $24.89 $415,872 - $768,453	30,874 Added 210.07%	45,571 $1.05 Million
Q3 2020 Nov 16, 2020	BUY	$12.89 - $15.89 $87,755 - $108,179	6,808 Added 86.3%	14,697 $208,000
Q2 2020 Aug 12, 2020	BUY	$8.86 - $15.69 $69,896 - $123,778	7,889 New	7,889 $119,000

311

314M

516K

833K

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.53B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.